Men Can Get Breast Cancer Too — Take Charge of Your Treatment
Breast cancer occurs mainly in women, but men can get it too. Many people do not realize that men have breast tissue and can develop breast cancer. Less than 1% of all breast cancers occur in men. For men, the lifetime risk of being diagnosed with breast cancer is about 1 in 1,000.1
The same treatments that are used in treating breast cancer in women are also used in men. In order to make the right treatment decision for you, it is important that you take an active role in learning all that you can about your individual cancer. You can take charge. You should gather as much information as you can about your diagnosis and possible breast cancer treatment options in order to make a more informed decision about your care. This website offers information that may help you understand the unique nature of your breast cancer and to empower you with the tools and information you need to confidently choose your course of treatment.
Genomic Testing with Oncotype DX
If you have been diagnosed with early-stage invasive breast cancer, the Oncotype DX test may be appropriate for you. The Oncotype DX test is a genomic breast cancer test that looks at the activity of certain genes in your tumor and provides personalized information that is not available from any other test or measure. A large study revealed that the genomic signature in men with breast cancer is similar to the signature in women with breast cancer, further supporting that the Oncotype DX test for breast cancer can also help guide treatment decisions for men with breast cancer.2
The Oncotype DX test is the only genomic test shown to predict the likelihood that you will benefit from adjuvant chemotherapy, while also determining the chance that your breast cancer will return. Along with the information in your pathology report and other factors, your Oncotype DX test results can help you and your doctor select the best treatment plan for you.
1 Cancer Facts & Figures 2014, American Cancer Society; 2014.
2Shak et al. 2009, ASCO.